FibroBiologics, Inc. (NASDAQ:FBLG) Shares Bought by State Street Corp

State Street Corp lifted its position in shares of FibroBiologics, Inc. (NASDAQ:FBLG) by 26.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 475,837 shares of the company’s stock after acquiring an additional 99,789 shares during the quarter. State Street Corp owned 1.35% of FibroBiologics worth $1,470,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in FBLG. Fund Evaluation Group LLC acquired a new position in FibroBiologics during the 2nd quarter worth approximately $5,265,000. Bank of New York Mellon Corp purchased a new stake in shares of FibroBiologics in the second quarter valued at approximately $342,000. Mercer Global Advisors Inc. ADV acquired a new position in FibroBiologics during the second quarter worth $51,000. Concurrent Investment Advisors LLC purchased a new position in FibroBiologics in the second quarter worth $176,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in FibroBiologics in the third quarter valued at $32,000.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Maxim Group began coverage on shares of FibroBiologics in a research note on Tuesday, September 24th. They set a “buy” rating and a $12.00 price target on the stock. D. Boral Capital restated a “buy” rating and set a $16.00 target price on shares of FibroBiologics in a research report on Friday, December 27th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of FibroBiologics in a research report on Wednesday, November 13th. Finally, Rodman & Renshaw began coverage on FibroBiologics in a research note on Thursday, December 12th. They set a “buy” rating and a $12.00 price target on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $13.00.

FibroBiologics Price Performance

Shares of NASDAQ FBLG opened at $1.99 on Friday. The company’s 50-day moving average price is $2.59 and its 200 day moving average price is $3.14. FibroBiologics, Inc. has a 52 week low of $1.08 and a 52 week high of $55.00.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.